Victoria Castel

List of Publications by Year
in descending order

58 papers	6,106 citations	201674 27 h-index	133252 59 g-index
61 all docs	61 docs citations	61 times ranked	4807 citing authors

#	Article	IF	Citations
1	Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes. Neoplasia, 2021, 23, 12-20.	5.3	3
2	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	1.6	30
3	Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. Journal of Clinical Oncology, 2021, 39, 2552-2563.	1.6	42
4	Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?. International Journal of Molecular Sciences, 2021, 22, 9815.	4.1	4
5	Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care. Cancers, 2021, 13, 5339.	3.7	7
6	Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma. Cancers, 2021, 13, 5173.	3.7	8
7	Liâ€"Fraumeni syndrome heterogeneity. Clinical and Translational Oncology, 2020, 22, 978-988.	2.4	18
8	Review: Ewing Sarcoma Predisposition. Pathology and Oncology Research, 2020, 26, 2057-2066.	1.9	11
9	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer, 2020, 135, 89-97.	2.8	13
10	Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. Journal of Clinical Oncology, 2020, 38, 2902-2915.	1.6	60
11	MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients. International Journal of Molecular Sciences, 2020, 21, 2714.	4.1	9
12	Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers, 2020, 12, 309.	3.7	84
13	Clinical Features of Neuroblastoma with 11q Deletion: An Increase in Relapse Probabilities in Localized and 4S Stages. Scientific Reports, 2019, 9, 13806.	3.3	15
14	Pharmacogenetics implementation in the clinics: information and guidelines for germline variants. , 2019, 2, 53-68.		7
15	Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project. Clinical and Translational Oncology, 2018, 20, 1046-1052.	2.4	4
16	Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1617-1629.	10.7	252
17	Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers, 2018, 10, 387.	3.7	13
18	Letter to the Editor. Clinical and Translational Oncology, 2018, 20, 1626-1627.	2.4	0

#	Article	IF	Citations
19	Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. British Journal of Cancer, 2018, 118, 1502-1512.	6.4	28
20	Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study. Cancer Research and Treatment, 2018, 50, 148-155.	3.0	46
21	Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?. Clinical and Translational Oncology, 2017, 19, 76-83.	2.4	10
22	Advances in emerging drugs for the treatment of neuroblastoma. Expert Opinion on Emerging Drugs, 2017, 22, 63-75.	2.4	36
23	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 500-514.	10.7	256
24	TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 573-580.	2.5	28
25	Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort. British Journal of Cancer, 2016, 115, 480-489.	6.4	46
26	The new challenge in oncology: Next-generation sequencing and its application in precision medicine. Anales De PediatrÃa (English Edition), 2016, 85, 273.e1-273.e7.	0.2	2
27	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. Journal of Neuroimmunology, 2016, 297, 98-102.	2.3	3
28	Paediatric tumour boards in Spain: a national survey. Clinical and Translational Oncology, 2016, 18, 931-936.	2.4	3
29	Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Oncogene, 2016, 35, 1423-1432.	5.9	27
30	Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors. Oncotarget, 2016, 7, 19935-19947.	1.8	22
31	Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration. Neoplasia, 2014, 16, 471-480.	5.3	25
32	Emerging drugs for neuroblastoma. Expert Opinion on Emerging Drugs, 2013, 18, 155-171.	2.4	22
33	Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion. PLoS ONE, 2013, 8, e53740.	2.5	33
34	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	6.4	82
35	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 2011, 29, 3286-3292.	1.6	248
36	Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1263-1272.	2.5	19

#	Article	IF	Citations
37	Neuroblastoma in adolescents: genetic and clinical characterisation. Clinical and Translational Oncology, 2010, 12, 49-54.	2.4	28
38	Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clinical and Translational Oncology, 2010, 12, 788-793.	2.4	20
39	Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study. Journal of Clinical Oncology, 2010, 28, 3516-3524.	1.6	114
40	Poor Survival for Infants With MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. Journal of Clinical Oncology, 2009, 27, 1014-1019.	1.6	123
41	Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatric Blood and Cancer, 2009, 52, 209-214.	1.5	12
42	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 289-297.	1.6	1,540
43	Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification. Journal of Clinical Oncology, 2009, 27, 1034-1040.	1.6	134
44	28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplantation, 2008, 41, S118-S127.	2.4	88
45	Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. British Journal of Cancer, 2008, 99, 1027-1033.	6.4	110
46	Molecular biology of neuroblastoma. Clinical and Translational Oncology, 2007, 9, 478-483.	2.4	42
47	Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 410-420.	2.8	35
48	Tumour banks in pediatric oncology. Clinical and Translational Oncology, 2006, 8, 884-888.	2.4	7
49	The Doublecortin Gene, A New Molecular Marker to Detect Minimal Residual Disease in Neuroblastoma. Diagnostic Molecular Pathology, 2005, 14, 53-57.	2.1	41
50	A comparison of current neuroblastoma chemotherapeutics. Expert Opinion on Pharmacotherapy, 2004, 5, 71-80.	1.8	16
51	MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genetics and Cytogenetics, 2003, 140, 157-161.	1.0	30
52	Minimal Residual Disease in Neuroblastoma: To GAGE or not to GAGE. Oncology Research, 2003, 14, 291-295.	1.5	9
53	The role of surgery in stage IV neuroblastoma. Journal of Pediatric Surgery, 2002, 37, 1574-1578.	1.6	80
54	Outcome of high-risk neuroblastoma using a dose intensity approach: Improvement in initial but not in long-term results. Medical and Pediatric Oncology, 2001, 37, 537-542.	1.0	48

#	Article	IF	Citations
55	Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting. European Journal of Cancer, 1999, 35, 606-611.	2.8	32
56	Surgical treatment for neuroblastoma: Complications during 15 years' experience. Journal of Pediatric Surgery, 1998, 33, 1526-1530.	1.6	38
57	Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: A report from the neuroblastoma group of the spanish society of pediatric oncology. Medical and Pediatric Oncology, 1995, 24, 29-35.	1.0	23
58	Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.. Journal of Clinical Oncology, 1993, 11, 1466-1477.	1.6	1,997